A new collaboration with AstraZeneca could give microbiome-based medicine a big lift.
News & Analysis: Seres Therapeutics
MCRB earnings call for the period ending December 31, 2018.
Results from a phase 1 study failed to impress investors.
These stocks climbed even though the broader market eased lower. Find out why.
A second chance granted by the FDA could be just what the company needs.
Investors bid up shares in response to a bullish analyst note.
Investors of Seres Therapeutics, Ford Motor Company, and Infinera could probably use a stiff drink after this week.
Shares plunged in reaction to important study results that missed the mark.
2015 was not a particularly strong year for IPOs, but these five did quite well.